Overview of Nova Eye Medical's Announcement

Nova Eye Medical Limited (ASX: $EYE) has announced the deferral of the implementation date of the final draft of the local coverage determination (LCD) issued by National Government Services (NGS) from December 23, 2023, to March 23, 2024. NGS administers the insurance reimbursement claims of healthcare facilities in several states, and the deferral is expected to impact the sales of the Company's iTrack™ portfolio of canaloplasty devices in the near term.

Executive Commentary on NGS Medicare Changes

The deferral of the implementation date of the final draft of the local coverage determination (LCD) by NGS is a positive development for Nova Eye Medical. This decision allows more time for the Company to navigate the potential impact of the proposed changes on its iTrack™ portfolio of canaloplasty devices. We are closely monitoring the situation and will continue to engage with NGS to ensure the best outcome for our products and patients.

Summary of Nova Eye Medical's Announcement

Nova Eye Medical (ASX: $EYE) has announced the deferral of the implementation date of the final draft of the local coverage determination (LCD) issued by National Government Services (NGS) from December 23, 2023, to March 23, 2024. The deferral by NGS is expected to positively impact the near-term sales of the Company's iTrack™ portfolio of canaloplasty devices. The Company remains focused on navigating the potential impact of the proposed changes and will continue to engage with NGS to ensure the best outcome for its products and patients.